Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 05, 2016; 86 (16 Supplement) April 21, 2016

24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase (S49.004)

Ayman Tourbah, Christine Lebrun-Frenay, Gilles Edan, Michel Clanet, Caroline Papeix, Sandra Vukusic, Jerome De Seze, Marc Debouverie, Olivier Gout, Pierre Clavelou, Gilles Defer, David Laplaud, Thibault Moreau, Pierre Labauge, Bruno Brochet, Frederic Sedel, Jean Pelletier
First published April 4, 2016,
Ayman Tourbah
7Neurology CHU Reims Reims France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Lebrun-Frenay
5Neurology CHU Nice Nice France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Edan
1France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Clanet
6Neurology CHU Purpan Toulouse France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Papeix
10GH Pitie Salpetriere Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Vukusic
14Hospital Neuro P Wertheimer Lyon France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerome De Seze
8Neurology CHU Strasbourg Strasbourg France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Debouverie
13Hospital Central Nancy France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Gout
9Fondation De Rothschild Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Clavelou
12Hopital Gabriel Montpied Clermont Ferrand France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Defer
11Hopital Cote De Nacre Caen France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Laplaud
4CHU Nantes Nantes France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thibault Moreau
2Neurology CHU Dijon Dijon France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Labauge
3CHU Motpellier Nimes, Cedex 4 France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Brochet
15Hospital Pellegrin, Neurology Dept Bordeaux France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederic Sedel
17MedDay Pharmaceuticals Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Pelletier
16Hospital Timone Adultes Marseille, Cedex 5 France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase (S49.004)
Ayman Tourbah, Christine Lebrun-Frenay, Gilles Edan, Michel Clanet, Caroline Papeix, Sandra Vukusic, Jerome De Seze, Marc Debouverie, Olivier Gout, Pierre Clavelou, Gilles Defer, David Laplaud, Thibault Moreau, Pierre Labauge, Bruno Brochet, Frederic Sedel, Jean Pelletier
Neurology Apr 2016, 86 (16 Supplement) S49.004;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objectives: To present the results at 24 months of the MS-SPI trial Background: High dose of Biotin, a co-enzyme for acetylCoA carboxylase, a potentially key-enzyme in myelin synthesis was investigated in progressive MS in a randomized placebo-controlled trial (MS-SPI). Results at 12 months demonstrated improvement of a significant proportion of patients (p=0.005), decreased mean change EDSS (p=0.014) and stabilisation of the clinical global impression of change (p<0.0001). Methods: MS-SPI is a randomized, double-blind, placebo-controlled (2:1) trial of oral biotin 300 mg / day in patients with secondary (SPMS) or primary (PPMS) progressive MS. Duration of the placebo-controlled was 48 weeks. The blinded phase was followed by a 12 months pre-planned extension phase where patients under placebo were switched to receive MD1003. Patients and physicians remained blinded to the treatment administered during the first phase of the study. Results: The last patient will complete the study in December 2015. The database will be locked in January 2016. Full statistical analyses will be available by March 2016. Results of clinical endpoints will be presented and discussed in the context of other trials in progressive MS. Conclusions: The 24-month results of the MS-SPI trial will be discussed in the context of development of high doses of pharmaceutical grade biotin as a novel treatment for progressive MS. Study supported by MedDay Pharmaceuticals

Disclosure: Dr. Tourbah has received personal compensation for activities with Biogen Idec, MedDay Pharmaceuticals, Sanofi-Genzyme, Novartis, Merck Serono, and Teva Pharma as a consultant/lecturer. Dr. Lebrun Frenay has nothing to disclose. Dr. Edan has nothing to disclose. Dr. Clanet has nothing to disclose. Dr. Papeix has nothing to disclose. Dr. Vukusic has received personal compensation for activities with Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis, and Teva Neuroscience. Dr. De Seze has nothing to disclose. Dr. Debouverie has received research support from Biogen Idec, Genyzyme, Merk Serono, and Novartis. Dr. Gout has nothing to disclose. Dr. Clavelou has received personal compensation for activities with Genzyme, Teva, Novartis, Almirall, and Biogen Idec. Dr. Defer has received research support from Novartis and Merck Serono Dr. Laplaud has nothing to disclose. Dr. Moreau has received personal compensation for activities with Biogen Idec, Sanofi-Aventis Pharmaceuticals, Genzyme corporation, Teva Neuroscience, Bayer Schering, Merck Serono, Novartis, and Almirall as a consultant. Dr. Labauge has nothing to disclose. Dr. Brochet has received personal compensation for activities with Biogen, Novartis, Teva, Genzyme, Merck Serono Roche, Bayer as a consultant and speaker. Dr. Sedel holds stock and/or stock options in Medday Pharmaceuticals. Dr. Pelletier has nothing to disclose.

Thursday, April 21 2016, 1:00 pm-3:00 pm

  • Copyright © 2016 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (3)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise